Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
STAMFORD, Conn., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
pruritus
, today announced the Company will host an in-person and virtual Capital Markets Day in New York City on Thursday, February 16, 2023, from 10:00 a.m. to 1:00 p.m. EST.
The event will highlight the launch of KORSUVA® (difelikefalin) injection and feature presentations during which healthcare providers will discuss the unmet medical need in
pruritus
associated with non-dialysis dependent
chronic kidney disease
,
atopic dermatitis
and
notalgia paresthetica
. The Company’s registrational Phase 2/3 program of oral difelikefalin in
notalgia paresthetica
patients with moderate-to-severe
pruritus
will also be discussed.
Presenters will include:
Christopher Posner, President and Chief Executive Officer, Cara Therapeutics
Joel Topf, M.D., FACP, Assistant Clinical Professor of Medicine at Oakland University William Beaumont School of Medicine, and Medical Director of St. Clair Nephrology Research
Jennifer Scherer, M.D., Assistant Professor of Palliative Care and Nephrology at the NYU Grossman School of Medicine, and Director of the Kidney CARES Program at NYU Langone Health
A live webcast of the event will be accessible under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. A replay of the webcast will be archived on the Company’s website following the event.
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
pruritus
. The Company’s novel KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe
pruritus
associated with
chronic kidney disease
in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of
pruritus
in patients with non-dialysis dependent advanced
chronic kidney disease
and
atopic dermatitis
. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe
pruritus
in patients with notalgia paresthetica and plans to initiate a Phase 2/3 clinical trial program in the first quarter of 2023. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.